slides · global inventory
Turn
Beat collection for the active corpus filters, with each row opening the slide detail view.
Matching slides 37,461
Current window 24,541-24,570
Pages 1,249
Rows per page 30
Beat
24,541-24,570 of 37,461
20
The slide uses a combination of bar charts and a process flow to illustrate growth and efficiency targets.Hugo Boss | Investor Day Presentation Deck | 107 slides · Hugo Boss
Conference presentation Investor relations Beat · SatisfactionLoop · Cost Of Inaction1 hit
06
The slide uses a process-like flow to connect technical features to quantitative performance outcomes.Hyzon | Investor Conference Presentation Deck | 24 slides · Hyzon
Conference presentation Investor relations Beat · SolutionLoop · Zoom In1 hit
07
The slide uses a horizontal timeline to track progress against specific technical and production milestones.Hyzon | Investor Conference Presentation Deck | 24 slides · Hyzon
Conference presentation Investor relations Beat · SolutionLoop · Zoom In1 hit
08
Uses a process flow diagram to explain the capital-light manufacturing strategy.Hyzon | Investor Conference Presentation Deck | 24 slides · Hyzon
Conference presentation Investor relations Beat · SolutionLoop · Zoom In1 hit
09
The slide uses a stacked bar chart to illustrate cost structure and contribution margin for different fuel cell configurations.Hyzon | Investor Conference Presentation Deck | 24 slides · Hyzon
Conference presentation Investor relations Beat · SolutionLoop · Zoom In1 hit
13
The slide uses a matrix-like structure to map strategic initiatives against time and recurrence.Hyzon | Results Presentation Deck | 19 slides · Hyzon
Conference presentation Investor relations Beat · The Breakthrough1 hit
37
Immix Biopharma | Investor Presentation Deck | 49 slidesImmix Biopharma | Investor Presentation Deck | 49 slides · Immix Biopharma
Pitch deck Investor relations Beat · Solution & Approach1 hit
38
The slide uses a process-oriented layout to connect platform capabilities to specific product outputs.Immix Biopharma | Investor Presentation Deck | 49 slides · Immix Biopharma
Pitch deck Investor relations Beat · Solution & Approach1 hit
39
The slide uses a process-like flow from the 3 pillars to the specific product applications.Immix Biopharma | Investor Presentation Deck | 49 slides · Immix Biopharma
Pitch deck Investor relations Beat · Solution & Approach1 hit
40
Includes technical diagrams of the drug construct, comparative histology, and survival curves.Immix Biopharma | Investor Presentation Deck | 49 slides · Immix Biopharma
Pitch deck Investor relations Beat · Solution & Approach1 hit
41
Includes two sets of charts: tumor volume line graphs and survival curves. References Abouzeid et al. (2013/2014).Immix Biopharma | Investor Presentation Deck | 49 slides · Immix Biopharma
Pitch deck Investor relations Beat · Solution & Approach1 hit
42
Includes detailed scientific diagrams and references to clinical studies.Immix Biopharma | Investor Presentation Deck | 49 slides · Immix Biopharma
Pitch deck Investor relations Beat · Solution & Approach1 hit
43
Immix Biopharma | Investor Presentation Deck | 49 slidesImmix Biopharma | Investor Presentation Deck | 49 slides · Immix Biopharma
Pitch deck Investor relations Beat · Solution & Approach1 hit
44
The slide uses a grid-like layout to present headshots, names, titles, and institutional logos for advisory board members.Immix Biopharma | Investor Presentation Deck | 49 slides · Immix Biopharma
Pitch deck Investor relations Beat · Solution & Approach1 hit
45
Immix Biopharma | Investor Presentation Deck | 49 slidesImmix Biopharma | Investor Presentation Deck | 49 slides · Immix Biopharma
Pitch deck Investor relations Beat · Solution & Approach1 hit
46
The slide is divided into two rows: top row for ImmixBio board members, bottom row for Nexcella board members.Immix Biopharma | Investor Presentation Deck | 49 slides · Immix Biopharma
Pitch deck Investor relations Beat · Solution & Approach1 hit
10
Includes a cartoon liver character at the bottom.Immix Biopharma | Investor Presentation Deck | 52 slides · Immix Biopharma
Pitch deck Investor relations Beat · SolutionLoop · Cost Of Inaction1 hit
11
Includes a footer citing FDA approval precedents for similar patient population sizes.Immix Biopharma | Investor Presentation Deck | 52 slides · Immix Biopharma
Pitch deck Investor relations Beat · Solution1 hit
12
Includes detailed clinical trial citations in the footer.Immix Biopharma | Investor Presentation Deck | 52 slides · Immix Biopharma
Pitch deck Investor relations Beat · Solution1 hit
13
The slide uses a standard pharmaceutical pipeline table format.Immix Biopharma | Investor Presentation Deck | 52 slides · Immix Biopharma
Pitch deck Investor relations Beat · Solution1 hit
14
The slide uses a two-column layout to track progress for two distinct drug programs.Immix Biopharma | Investor Presentation Deck | 52 slides · Immix Biopharma
Pitch deck Investor relations Beat · Solution1 hit
15
The slide uses a side-by-side comparison of two proprietary platforms.Immix Biopharma | Investor Presentation Deck | 52 slides · Immix Biopharma
Pitch deck Investor relations Beat · SolutionLoop · Golden Circle1 hit
16
Immix Biopharma | Investor Presentation Deck | 52 slidesImmix Biopharma | Investor Presentation Deck | 52 slides · Immix Biopharma
Pitch deck Investor relations Beat · SolutionLoop · Golden Circle1 hit
17
Includes comparative charts for transduction efficiency and anti-exhaustion capability.Immix Biopharma | Investor Presentation Deck | 52 slides · Immix Biopharma
Pitch deck Investor relations Beat · SolutionLoop · Golden Circle1 hit
18
Includes a comparative table of clinical outcomes (ORR/CR) for NXC-201 vs competitors.Immix Biopharma | Investor Presentation Deck | 52 slides · Immix Biopharma
Pitch deck Investor relations Beat · SolutionLoop · Golden Circle1 hit
19
Immix Biopharma | Investor Presentation Deck | 52 slidesImmix Biopharma | Investor Presentation Deck | 52 slides · Immix Biopharma
Pitch deck Investor relations Beat · Solution1 hit
20
The slide explicitly notes that these are cross-trial comparisons, not head-to-head studies.Immix Biopharma | Investor Presentation Deck | 52 slides · Immix Biopharma
Pitch deck Investor relations Beat · Solution1 hit
21
Includes detailed source citations and disclaimer regarding cross-trial comparisons.Immix Biopharma | Investor Presentation Deck | 52 slides · Immix Biopharma
Pitch deck Investor relations Beat · Solution1 hit
22
The slide uses a comparison table framework to highlight NXC-201's competitive advantage in safety (lower ICANS/CRS) and efficacy (higher ORR/CR).Immix Biopharma | Investor Presentation Deck | 52 slides · Immix Biopharma
Pitch deck Investor relations Beat · Solution1 hit
23
The slide uses a two-column layout to contrast clinical results for Multiple Myeloma vs. AL Amyloidosis, supported by market data for existing therapies.Immix Biopharma | Investor Presentation Deck | 52 slides · Immix Biopharma
Pitch deck Investor relations Beat · Solution1 hit